Johnson & Johnson's Ortho-McNeil Neurologics said a U.S. District Court has granted its request for a preliminary injunction to stop Mylan Laboratories Inc. from launching a generic version of Topamax
before the final court decision on the validity of the patent. The patent for Topamax, an anti-epileptic drug, expires September 2008. Ortho-McNeil said a trial date hasn't yet been set.
